Related Experiment Video
Updated: Aug 22, 2025
07:26
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
17.7K
Carvedilol-Induced Thrombocytopenia: A Case Report
Angelina R Raimonde1, Anthony K Dennis1
1Rush University Medical Center, Chicago, IL, USA.
Hospital Pharmacy
|November 7, 2022
Summary
Drug-induced thrombocytopenia (DITP) is a serious complication. A case study highlights carvedilol as a potential cause, emphasizing prompt diagnosis and management for patient recovery.
Area of Science:
- Hematology
- Pharmacology
- Internal Medicine
Background:
- Thrombocytopenia, a low platelet count, is common in hospitalized patients.
- It can stem from infections, surgery, or medications, necessitating consideration of drug-induced thrombocytopenia (DITP).
- DITP mechanisms include direct effects on bone marrow thrombopoiesis or antibody-mediated platelet destruction.
Observation:
- A 44-year-old female presented with nausea, vomiting, and headaches during hemodialysis.
- She was found to have severe thrombocytopenia (35 K/µL), a significant drop from her baseline (299 K/µL).
- Initial investigations for other causes of thrombocytopenia were negative.
Findings:
- A newly initiated carvedilol prescription was identified as the likely cause of thrombocytopenia.
- Platelet count rapidly recovered after discontinuation of carvedilol.
- This suggests a drug-dependent antibody-mediated mechanism.
Implications:
- Highlights the importance of considering DITP in patients with unexplained thrombocytopenia, especially after starting new medications.
- Carvedilol should be recognized as a potential cause of DITP.
- Prompt identification and withdrawal of the offending drug are crucial for successful patient outcomes.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
602
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
602
01:17Pericarditis III: Medical Management
22
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
22
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
26
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
26
01:30Coronary Artery Disease III: Clinical Manifestations
25
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
25
01:19Pericarditis II: Clinical Features and Diagnostic Tests
19
Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...
19
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
24
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
24